The impact of injecting drug use status on hepatitis C-related referral and treatment

Drug and Alcohol Dependence

Volumn 77, Issue 1, 2005, Pages 81-86

  Stoove M A ^a   Gifford, S M ^b   Dore, G J ^c  

^a Turning Point Alcohol Drug Ctr Inc   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Hepatitis C; Injecting drug use; Referral; Treatment

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; AUSTRALIA; CONSULTATION; CONTROLLED STUDY; DRUG ABUSE; DRUG ADMINISTRATION ROUTE; FEMALE; GENERAL PRACTITIONER; HEALTH SERVICE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT REFERRAL; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; SELF EVALUATION; SEX ROLE;

ADULT; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRES; REFERRAL AND CONSULTATION; RESIDENCE CHARACTERISTICS; SUBSTANCE ABUSE, INTRAVENOUS;

HEPATITIS C VIRUS; VICTORIA;

EID: 10644220356     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2004.07.002     Document Type: Article

References (24)

1. ANCHARD, 2002. Hepatitis C virus projections working group: estimates and projections of the hepatitis C virus epidemic in Australia 2002. Australian National Council on AIDS, Hepatitis C and Related Diseases, Hepatitis C Sub-Committee. Commonwealth Government of Australia, Canberra.
2. ANCHARD, 2003. A model of care for the management of hepatitis C infection in adults. Australian National Council on AIDS, Hepatitis C and Related Diseases, Hepatitis C Sub-Committee. Commonwealth Government of Australia, Canberra.
3. M.S. Bayliss, B. Gandek, K.M. Bungay, D. Sugano, M.A. Hsu, and J.E. Ware A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C Qual. Life Res. 7 1998 39 55
4. C.A. Chong, A. Gulamhussein, E.J. Heathcote, L. Lilly, M. Sherman, G. Naglie, and M. Krahn Health-state utilities and quality of life in hepatitis C patients Am. J. Gastroenterol. 98 2003 630 638
5. N. Crofts, R. Louie, and B. Loff The next plague: stigmatization and discrimination related to hepatitis C virus infection in Australia Health Hum. Rights 2 1997 87 97
6. G.J. Dore, A.J. Freeman, M. Law, and J.M. Kaldor Is severe liver disease a common outcome for people with chronic hepatitis C? J. Gastroenterol. Hepatol. 17 2002 423 430
7. B.R. Edlin Prevention and treatment of hepatitis C in injection drug users Hepatology 36 2002 S210 S219
8. G.R. Foster, R.D. Goldin, and H.C. Thomas Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis Hepatology 27 1998 209 212
9. S.M. Gifford, M.L. O'Brien, G. Bammer, C. Banwell, and M. Stoové Australian women's experiences of living with hepatitis C virus: results from a cross-sectional survey J. Gastroenterol. Hepatol. 18 2003 841 850
10. M. Hara, S. Sasaki, T. Sobue, S. Yamamoto, and S. Tsugane Comparison of cause-specific mortality between respondents and non-respondents in a population-based prospective study: ten-year follow-up of JPHC Study Cohort I J. Clin. Epidemiol. 55 2002 150 156
11. M.G. Law, G.J. Dore, N. Bath, S. Thompson, N. Crofts, K. Dolan, W. Giles, P. Gow, J. Kaldor, S. Loveday, E. Powell, J. Spencer, and A. Wodak Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia J. Epidemiol. 32 2003 717 724
12. J.G. McHutchison, and M.W. Fried Current therapy for hepatitis C: pegylated interferon and ribavirin Clin. Liver Dis. 7 2003 149 161
13. NCHECR, 2002. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2002. National Centre in HIV Epidemiology and Clinical Research (NCHECR), The University of New South Wales, Sydney.
14. M.P. Neary, S. Cort, M.S. Bayliss, and J.E. Ware Jr. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients Semin. Liver Dis. 19 1999 77 86
15. M. Perez-Olmeda, M. Nunez, M. Romero, J. González, A. Castro, J.R. Arribas, J. Pedreira, P. Barreiro, J. García-Samaniego, L. Martín-Carbonero, I. Jiménez-Nácher, and V. Soriano Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients Aids 17 2003 1023 1028
16. T. Poynard, J. McHutchison, M. Manns, C. Trepo, K. Lindsay, Z. Goodman, M.H. Ling, and J. Albrecht Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.[comment] Gastroenterology 122 2002 1303 1313
17. J. Rasenack, S. Zeuzem, S.V. Feinman, E.J. Heathcote, M. Manns, E.M. Yoshida, M.G. Swain, E. Gane, M. Diago, D.A. Revicki, A. Lin, N. Wintfeld, and J. Green Peginterferon a-2a (40 kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon a-2a [Roferon-A]: In patients with chronic hepatitis C Pharmacoeconomics 21 2003 341 349
18. M. Schaefer, F. Schmidt, C. Folwaczny, R. Lorenz, G. Martin, N. Schindlbeck, W. Heldwein, M. Soyka, H. Grunze, A. Koenig, and K. Loeschke Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups Hepatology 37 2003 443 451
19. L.B. Seeff Natural history of chronic hepatitis C Hepatology 36 2002 S35 S46
20. A.J. Søgaard, R. Selmer, E. Bjertness, and D. Thelle The Oslo Health Study: The impact of self-selection bias in a large population-based survey Int. J. Equity Health 3 2004 3 15
21. SPSS for Windows, Rel. 10.0.0, SPSS Inc., Chicago, 1999.
22. D.L. Sylvestre Treating hepatitis C in methadone maintenance patients: an interim analysis Drug Alcohol Depend. 67 2002 117 123
23. A.J. van Loon, M. Tijhuis, H.S. Picavet, P.G. Surtees, and J. Ormel Survey non-response in the Netherlands. Effects on prevalence estimates and associations Ann. Epidemiol. 13 2003 105 110
24. J. Ware Jr., M. Kosinski, and S.D. Keller A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity Med. Care 34 1996 220 233